ClinicalTrials.gg

Program

lurasidone

Also written as “Lurasidone”, “Lurasidone HCl” and “SM-13496”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Depression · Urinary Tract Infections, led by 4 companies.

Furthest: phase 4, since Aug 7, 202152 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sumitomo Pharma480 open or runningphase 4since Aug 7, 2021Aug 16, 2002none ahead
Bukwang Pharmaceutical21 open or runningphase 3since Mar 8, 2018Mar 8, 2018Oct 2027phase 3 · NCT07781293
NeuroRx11 open or runningphase 2since Nov 7, 2023Nov 7, 2023none ahead
Standard Chem. & Pharm.10 open or runningphase 4since Dec 20, 2017Dec 20, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 34 studies since Aug 16, 2002.

  1. Mar 22, 2013Phase 3 study in SchizophreniaSumitomo Pharma · NCT01821378 · 412 enrolled · United States, Colombia, Romania and more
  2. Jul 22, 20133 phase 3 studiesSumitomo Pharma · NCT01911442, NCT01911429, NCT01914393
  3. Nov 4, 20132 phase 3 studiesSumitomo Pharma · NCT01986114, NCT01986101
  4. Dec 2, 2013Phase 3 study in SchizophreniaSumitomo Pharma · NCT02002832 · 388 enrolled · China
  5. Jan 23, 2014Phase 3 study in Bipolar DisorderSumitomo Pharma · NCT02046369 · 350 enrolled · United States, Bulgaria, Colombia and more
  6. Feb 11, 20142 phase 1 studies in SchizophreniaSumitomo Pharma · NCT02174523, NCT02174510
  7. Dec 20, 2017Standard Chem. & Pharm.'s first study: phase 4 study in SchizophreniaNew to Standard Chem. & Pharm.Standard Chem. & Pharm. · NCT03393026 · 54 enrolled · Taiwan
  8. Mar 8, 2018Bukwang Pharmaceutical's first study: phase 3 study in SchizophreniaNew to Bukwang PharmaceuticalBukwang Pharmaceutical · NCT03465787 · 210 enrolled · Korea, Republic of
  9. Aug 7, 2018Phase 1 study in SchizophreniaSumitomo Pharma · NCT03627195 · 40 enrolled · United States
  10. Apr 16, 2020Phase 3 study in Bipolar I DepressionSumitomo Pharma · NCT04383691 · 124 enrolled · China
  11. Aug 7, 2021Phase 4 study in SchizophreniaSumitomo Pharma · NCT05011669 · 200 enrolled · China
  12. Dec 5, 2021Phase 4 study in SchizophreniaSumitomo Pharma · NCT05213143 · 13 enrolled · China
  13. Nov 7, 2023NeuroRx's first study: phase 2 study in Urinary Tract InfectionsNew to NeuroRxNeuroRx · NCT06128213 · 13 planned
  14. Aug 6, 2026Phase 3 study in Depressive Disorder, MajorBukwang Pharmaceutical · NCT07781293 · 364 planned

Ahead

  1. Oct 2027Primary completion: phase 3 study in Depressive Disorder, MajorBukwang Pharmaceutical · NCT07781293

TargetBeta

DRD2 →HTR2A →read by rule
“Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
iloperidoneruleVanda Pharmaceuticalsphase 415
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 52 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07781293Depressive Disorder, Major3Not yet recruitingBukwang PharmaceuticalOct 2027364
NCT06128213Urinary Tract Infections2Not yet recruitingNeuroRxJun 30, 202413
NCT05213143Schizophrenia · China4TerminatedSumitomo PharmaNov 18, 202213
NCT05011669Schizophrenia · China4CompletedSumitomo PharmaApr 16, 2023200
NCT04383691Bipolar I Depression · China3TerminatedSumitomo PharmaDec 23, 2022124
NCT03627195Schizophrenia · United States1CompletedSumitomo PharmaMar 29, 201940
NCT03465787Schizophrenia · Korea, Republic of3CompletedBukwang PharmaceuticalOct 26, 2022210
NCT03393026Schizophrenia · Taiwan4CompletedStandard Chem. & Pharm.Sep 17, 201954
NCT02174523Schizophrenia · China1CompletedSumitomo PharmaApr 201414
NCT02174510Schizophrenia · China1CompletedSumitomo PharmaApr 201437
NCT02046369Bipolar Disorder · United States, Bulgaria, Colombia and more3CompletedSumitomo PharmaOct 2016350
NCT02002832Schizophrenia · China3CompletedSumitomo PharmaApr 2015388
NCT01986114Bipolar I Disorder · Japan, Lithuania, Malaysia and more3CompletedSumitomo PharmaFeb 8, 2018495
NCT01986101Bipolar Disorder · Japan, Lithuania, Malaysia and more3CompletedSumitomo PharmaFeb 1, 2017525
NCT01914393Schizophrenia · United States, Bulgaria, Colombia and more3CompletedSumitomo PharmaOct 17, 2018702
NCT01911442Autistic Disorder · United States3CompletedSumitomo PharmaNov 2014150
NCT01911429Schizophrenia · United States, Belgium, Bulgaria and more3CompletedSumitomo PharmaDec 2015327
NCT01821378Schizophrenia · United States, Colombia, Romania and more3CompletedSumitomo PharmaJun 2014412
NCT01614912Schizophrenia · Japan, Korea, Republic of, Malaysia and more3CompletedSumitomo PharmaMay 2015284
NCT01614899Schizophrenia · Japan, Korea, Republic of, Malaysia and more3CompletedSumitomo PharmaNov 17, 2014457
NCT01620060Schizophrenia · United States1CompletedSumitomo PharmaMay 2013105
NCT01575561Bipolar Disorder · United States, Argentina, Bulgaria and more3CompletedSumitomo PharmaJul 2015377
NCT01566162Schizophrenia · United States, France, Italy and more3CompletedSumitomo PharmaNov 2013191
NCT01485640Schizophrenia · Canada, Colombia, Czech Republic and more3CompletedSumitomo PharmaFeb 2014162
NCT01435928Schizophrenia · United States, France, Italy and more3CompletedSumitomo PharmaAug 2013676
NCT01423253Depressive Disorder, Major · United States3CompletedSumitomo PharmaOct 201348
NCT01423240Depressive Disorder, Major · United States3WithdrawnSumitomo PharmaDec 20120
NCT01421134Depression · United States, Russian Federation, Serbia and more3CompletedSumitomo PharmaOct 2014211
NCT01358357Bipolar I Disorder · United States, Argentina, Australia and more3CompletedSumitomo PharmaApr 2015965
NCT01284517Bipolar Disorder · United States, Canada, Colombia and more3CompletedSumitomo PharmaAug 2012356
NCT01143090Schizophrenia · United States3CompletedSumitomo PharmaNov 2011149
NCT01143077Schizophrenia · United States3CompletedSumitomo PharmaMay 2011244
NCT01082289Schizophrenia · United States1CompletedSumitomo PharmaOct 200824
NCT01082276Male, Healthy Normal Subjects · United States1CompletedSumitomo PharmaAug 200820
NCT01082263Schizophrenia Patients · United States1CompletedSumitomo PharmaNov 200824
NCT01082250Schizophrenia · United States1CompletedSumitomo PharmaSep 200852
NCT01082146Pharmacokinetics · United States1CompletedSumitomo PharmaAug 20086
NCT01074632Schizophrenia · United States1CompletedSumitomo PharmaSep 200926
NCT01074073Schizophrenia · United States1CompletedSumitomo PharmaOct 200824
NCT00868959Bipolar Disorder · United States, Canada, Colombia and more3CompletedSumitomo PharmaFeb 2013817
NCT00868699Bipolar Disorder · United States, Czech Republic, France and more3CompletedSumitomo PharmaFeb 2012505
NCT00868452Bipolar Disorder · United States, Czech Republic, France and more3CompletedSumitomo PharmaDec 2011348
NCT00790192Schizophrenia · United States, India, Romania and more3CompletedSumitomo PharmaJul 2010488
NCT00711269Schizophrenia · Japan, Korea, Republic of, Taiwan3CompletedSumitomo PharmaApr 27, 2010460
NCT00641745Schizophrenia · United States, Argentina, Brazil and more3CompletedSumitomo PharmaJul 2010629
NCT00615433Schizophrenia · United States, Colombia, India and more3CompletedSumitomo PharmaDec 2009478
NCT00549718Schizophrenia · United States, France, India and more3CompletedSumitomo PharmaOct 2010489
NCT00549666Pharmacokinetics · United States1CompletedSumitomo PharmaDec 200723
NCT00088634Schizophrenia · United States2CompletedSumitomo PharmaDec 2004180
NCT00088621Schizophrenia · United States2CompletedSumitomo PharmaOct 200561
NCT00044044Schizophrenia · United States2CompletedSumitomo PharmaMay 2003356
NCT00044005Schizophrenia · United States2CompletedSumitomo PharmaNov 200398

How it is read

Names in the registry

  • “Lurasidone”, 22 entries
  • “Lurasidone HCl”, 10 entries
  • “SM-13496”, 4 entries
  • “Lurasidone 40 mg”, 3 entries
  • “lurasidone”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.